D'Amours Guylaine, Langlois Mathieu, Mathonnet Géraldine, Fetni Raouf, Nizard Sonia, Srour Myriam, Tihy Frédérique, Phillips Michael S, Michaud Jacques L, Lemyre Emmanuelle
Service de génétique médicale, CHU Sainte-Justine, Montréal, QC, Canada.
Centre de recherche, CHU Sainte-Justine, Montréal, QC, Canada.
BMC Med Genomics. 2014 Dec 24;7:70. doi: 10.1186/s12920-014-0070-0.
Molecular karyotyping is now the first-tier genetic test for patients affected with unexplained intellectual disability (ID) and/or multiple congenital anomalies (MCA), since it identifies a pathogenic copy number variation (CNV) in 10-14% of them. High-resolution microarrays combining molecular karyotyping and single nucleotide polymorphism (SNP) genotyping were recently introduced to the market. In addition to identifying CNVs, these platforms detect loss of heterozygosity (LOH), which can indicate the presence of a homozygous mutation or uniparental disomy. Since these abnormalities can be associated with ID and/or MCA, their detection is of particular interest for patients whose phenotype remains unexplained. However, the diagnostic yield obtained with these platforms is not confirmed, and the real clinical value of LOH detection has not been established.
We selected 21 children affected with ID, with or without congenital malformations, for whom standard genetic analyses failed to provide a diagnosis. We performed high-resolution SNP array analysis with four platforms (Affymetrix Genome-Wide Human SNP Array 6.0, Affymetrix Cytogenetics Whole-Genome 2.7 M array, Illumina HumanOmni1-Quad BeadChip, and Illumina HumanCytoSNP-12 DNA Analysis BeadChip) on whole-blood samples obtained from children and their parents to detect pathogenic CNVs and LOHs, and compared the results with those obtained on a moderate resolution array-based comparative genomic hybridization platform (NimbleGen CGX-12 Cytogenetics Array), already used in the clinical setting.
We identified a total of four pathogenic CNVs in three patients, and all arrays successfully detected them. With the SNP arrays, we also identified a LOH containing a gene associated with a recessive disorder consistent with the patient's phenotype (i.e., an informative LOH) in four children (including two siblings). A homozygous mutation within the informative LOH was found in three of these patients. Therefore, we were able to increase the diagnostic yield from 14.3% to 28.6% as a result of the information provided by LOHs.
This study shows the clinical usefulness of SNP arrays in children with ID, since they successfully detect pathogenic CNVs, identify informative LOHs that can lead to the diagnosis of a recessive disorder. It also highlights some challenges associated with the use of SNP arrays in a clinical laboratory.
分子核型分析目前是不明原因智力障碍(ID)和/或多发先天性畸形(MCA)患者的一线基因检测方法,因为它能在10% - 14%的此类患者中识别出致病性拷贝数变异(CNV)。结合分子核型分析和单核苷酸多态性(SNP)基因分型的高分辨率微阵列最近已投放市场。除了识别CNV外,这些平台还能检测杂合性缺失(LOH),这可能表明存在纯合突变或单亲二体。由于这些异常可能与ID和/或MCA相关,对于那些表型仍无法解释的患者来说,检测它们尤为重要。然而,这些平台获得的诊断率尚未得到证实,LOH检测的实际临床价值也尚未确立。
我们选择了21名患有ID、有或无先天性畸形的儿童,他们的标准基因分析未能得出诊断结果。我们使用四个平台(Affymetrix全基因组人类SNP Array 6.0、Affymetrix细胞遗传学全基因组2.7M阵列、Illumina HumanOmni1 - Quad BeadChip和Illumina HumanCytoSNP - 12 DNA分析芯片)对从儿童及其父母采集的全血样本进行高分辨率SNP阵列分析,以检测致病性CNV和LOH,并将结果与在临床环境中已使用的中等分辨率基于阵列的比较基因组杂交平台(NimbleGen CGX - 12细胞遗传学阵列)上获得的结果进行比较。
我们在三名患者中总共鉴定出四个致病性CNV,所有阵列均成功检测到它们。通过SNP阵列,我们还在四名儿童(包括两名兄弟姐妹)中鉴定出一个包含与隐性疾病相关基因的LOH(即信息性LOH),该隐性疾病与患者表型一致。在其中三名患者中发现信息性LOH内存在纯合突变。因此,由于LOH提供的信息,我们能够将诊断率从14.3%提高到28.6%。
本研究表明SNP阵列在患有ID的儿童中具有临床实用性,因为它们能成功检测致病性CNV,识别可导致隐性疾病诊断的确切LOH。它还突出了在临床实验室使用SNP阵列相关的一些挑战。